Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation

Slides:

Advertisements

Similar presentations

The Rise of Renal Pathology in Nephrology: Structure Illuminates Function Vivette D. D'Agati, MD, Michael Mengel, MD American Journal of Kidney Diseases.

Advertisements

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

American Journal of Kidney Diseases

Implementing KDOQI CKD Definition and Staging Guidelines in Southern California Kaiser Permanente Mark Rutkowski, MD, Wendy Mann, PharmD, Stephen Derose,

John W. Pickering, PhD, Matthew T. James, MD, PhD, FRCPC, Suetonia C

Fredrik Karlsson, MD, Angelo Modica, MD, Thomas Mooe, MD, PhD

Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.

Kidney Function and Cognitive Impairment in US Adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Manjula Kurella Tamura,

Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD Akshay S. Desai, MD, MPH,

Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.

Volume 94, Issue 3, Pages (September 2018)

Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase.

In Reply to ‘The Importance of Icodextrin Use for Technique and Patient Survival in Peritoneal Dialysis’ Emily J. See, MBBS, David W. Johnson, PhD, Yeoungjee.

Kidney Function and Cognitive Impairment in US Adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Manjula Kurella Tamura,

Olivier Niel, MD, PhD, Charlotte Boussard, MSc, Paul Bastard, MSc

Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline Krista L. Lentine, MD, PhD, Andrew S. Levey, MD,

Metabolic Complications in Elderly Adults With CKD

Development of Reduced Kidney Function in Rheumatoid Arthritis

Jessica W. Weiss, MD, Eric S. Johnson, PhD, Amanda Petrik, MS, David H

Francesca Mallamaci, MD, Giovanni Tripepi, PhD

Risk of ESRD and Mortality in Kidney and Bladder Stone Formers

A Decade After the KDOQI CKD Guidelines

World Kidney Day 2014: CKD and the Aging Population

NSAID Use and Progression of Chronic Kidney Disease

Cardiovascular Disease and CKD: Core Curriculum 2010

Matei Neagu, PhD, Daniel Coca, PhD, Albert C.M. Ong, DM

Risk Factors for ESRD in Individuals With Preserved Estimated GFR With and Without Albuminuria: Results From the Kidney Early Evaluation Program (KEEP)

What Is the Goal With Endogenous Filtration Markers—Estimation of GFR or Prediction of Kidney Outcomes? Andrew D. Rule, MD, MSc, Kent R. Bailey, PhD,

Patient and Graft Survival Following Kidney Transplantation in Recipients With Cystinosis: A Cohort Study Rebecca A. Spicer, MBChB, Philip A. Clayton,

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Sevelamer Prescriptions After Reporting of the Dialysis Clinical Outcomes Revisited (DCOR) Trial Findings: An Analysis of 5,495 Patients Receiving Maintenance.

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP) Richard.

A New Clinical Prediction Tool for 5-Year Kidney Transplant Outcome

Anne M. Butler, PhD, Andrew F. Olshan, PhD, Abhijit V

Volume 78, Issue 8, Pages (October 2010)

Differences in Use of Peritoneal Dialysis and Survival Among East Asian, Indo Asian, and White ESRD Patients in Canada Brenda R. Hemmelgarn, PhD, MD,

Your Kidneys May Outlive You

Hai-yan Wang, MD, American Journal of Kidney Diseases

Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study Martin J. Landray, PhD,

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Salt and Hypertension American Journal of Kidney Diseases

Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis Xiaole Su, MD, Lu Zhang, MD, Jicheng Lv, MD, PhD, Jinwei Wang, PhD,

Association of Waist Circumference and Body Mass Index With All-Cause Mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in.

Ioannis Koulouridis, MD, MS, Lori Lyn Price, MAS, Nicolaos E

Lifetime Incidence of CKD Stages 3-5 in the United States

Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients Fowzia Ibrahim, MSc, Lisa Hamzah, MRCP, Rachael.

The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis Kevin Quach,

Management of Heart Failure in Advancing CKD: Core Curriculum 2018

CKD as an Underrecognized Threat to Patient Safety

Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study Wolfgang.

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor.

Polyunsaturated Fatty Acids and Kidney Disease

U-shaped effect of eGFR and mortality

Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study Eric D.

Performance of GFR Estimating Equations Stratified by Measured or Estimated GFR: Implications for Interpretation Jonas Björk, PhD, Anders Grubb, MD,

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial

Christina L. Klein, MD, Daniel C. Brennan, MD, FACP

Evidence and Outcomes in CKD

Drug Dose Adjustments in Patients With Renal Impairment

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

Long-term Outcomes of Acute Kidney Injury: The Power and Pitfalls of Observational/Population-Based Studies Charuhas V. Thakar, MD American Journal.

Volume 80, Issue 12, Pages (December 2011)

Volume 83, Issue 3, Pages (March 2013)

Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults Sonja Gandhi, PhD, Salimah Z. Shariff, PhD,

Volume 74, Issue 3, Pages (August 2008)

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

Ann M. O'Hare, MA, MD American Journal of Kidney Diseases

Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients Colin R. Lenihan, MB BCh, PhD, Sumi Sukumaran Nair, MD, Chandan Vangala,

Presentation transcript:

Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation Min Jun, MScMed(ClinEpi), PhD, Matthew T. James, MD, PhD, Zhihai Ma, MSc, Jianguo Zhang, MSc, Marcello Tonelli, MD, SM, Finlay A. McAlister, MD, MSc, Braden J. Manns, MD, MSc, Pietro Ravani, MD, PhD, Robert R. Quinn, MD, PhD, Natasha Wiebe, MMath, PStat, Vlado Perkovic, MBBS, PhD, Stephen B. Wilton, MD, MSc, Wolfgang C. Winkelmayer, MD, ScD, Brenda R. Hemmelgarn, MD, PhD American Journal of Kidney Diseases Volume 69, Issue 6, Pages 734-743 (June 2017) DOI: 10.1053/j.ajkd.2016.10.018 Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Identification of study cohort. Abbreviations: AF, atrial fibrillation; ESRD, end-stage renal disease. American Journal of Kidney Diseases 2017 69, 734-743DOI: (10.1053/j.ajkd.2016.10.018) Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Study design. The index date for nonusers in the matched set corresponded to the date of their incident atrial fibrillation (AF) diagnosis plus the time between their matched user’s incident AF diagnosis date and the warfarin prescription date. American Journal of Kidney Diseases 2017 69, 734-743DOI: (10.1053/j.ajkd.2016.10.018) Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Incidence (number of events and rates per 100 person-years) of study outcomes by warfarin use and estimated glomerular filtration rate (eGFR) category. (A) All-cause death, ischemic stroke, or transient ischemic attack (TIA); (B) ischemic stroke or TIA; (C) all-cause death; and (D) major bleeding. Bars represent 95% confidence intervals (per 100 person-years) for incidence rates. American Journal of Kidney Diseases 2017 69, 734-743DOI: (10.1053/j.ajkd.2016.10.018) Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

Figure 4 Hazard ratios (HRs) for study outcomes by estimated glomerular filtration rate (eGFR) category. aOverall HRs and 95% CIs for the composite outcome: 0.60 (0.53-0.66). bOverall HRs and 95% CIs for stroke/TIA: 0.69 (0.55-0.86). cOverall HRs and 95% CIs for all-cause death: 0.58 (0.52-0.66). dOverall HRs and 95% CIs for major bleeding: 0.85 (0.74-0.99). Abbreviations: CI, confidence interval; TIA, transient ischemic attack. American Journal of Kidney Diseases 2017 69, 734-743DOI: (10.1053/j.ajkd.2016.10.018) Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions